| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |